Search

Your search keyword '"bluebird bio, Inc. -- Product development"' showing total 2 results
Start Over Descriptor "bluebird bio, Inc. -- Product development" Journal fiercebiotech.com

Refine your results

2 results on '"bluebird bio, Inc. -- Product development"'

1. Bluebird finds gene therapy 'very unlikely' to have caused AML, plans resumption of clinical trials

Author

Taylor, Nick Paul

Subjects
bluebird bio, Inc. -- Product development, Sickle cell anemia, Genes, Biotechnology industry -- Product development, Gene therapy, Clinical trials, Biotechnology industry
Abstract

Byline: Nick Paul Taylor A bluebird bio investigation has found (https://www.businesswire.com/news/home/20210310005286/en/bluebird-bio-Provides-Updated-Findings-from-Reported-Case-of-Acute-Myeloid-Leukemia-AML-in-LentiGlobin-for-Sickle-Cell-Disease-SCD-Gene-Therapy-Program) a LentiGlobin gene therapy is 'very unlikely' to have caused the acute myeloid leukemia (AML) that affected a recipient [...]

Published
2021

2. Bluebird stops gene therapy trials after 2 sickle cell patients develop cancer

Author

Taylor, Nick Paul

Subjects
bluebird bio, Inc. -- Product development, Sickle cell anemia, Genes, Biotechnology industry -- Product development, Gene therapy, Cancer -- Genetic aspects, Clinical trials, Biotechnology industry
Abstract

Byline: Nick Paul Taylor Bluebird bio has suspended (https://www.businesswire.com/news/home/20210216005442/en/bluebird-bio-Announces-Temporary-Suspension-on-Phase-12-and-Phase-3-Studies-of-LentiGlobin-Gene-Therapy-for-Sickle-Cell-Disease-bb1111) two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results